The online version of this article (https://doi.org/10.1186/s12935-017-0497-4) contains supplementary material, which is available to authorized users.
Xiaoqian Ji and Siyu Chen contributed equally to this work
Patient-derived xenografts (PDX) have a biologically stable in tumor architecture, drug responsiveness, mutational status and global gene-expression patterns. Numerous PDX models have been established to date, however their thorough characterization regarding the tumor formation and rates of tumor growth in the established models remains a challenging task. Our study aimed to provide more detailed information for establishing the PDX models successfully and effectively.
We transplanted four different types of solid tumors from 108 Chinese patients, including 21 glioblastoma (GBM), 11 lung cancers (LC), 54 gastric cancers (GC) and 21 colorectal cancers (CRC), and took tumor tissues passaged for three successive generations. Here we report the rate of tumor formation, tumor-forming times, tumor growth curves and mortality of mice in PDX model. We also report H&E staining and immunohistochemistry for HLA-A, CD45, Ki67, GFAP, and CEA protein expression between patient cancer tissues and PDX models.
Tumor formation rate increased significantly in subsequent tumor generations. Also, the survival rates of GC and CRC were remarkably higher than GBM and LC. As for the time required for the formation of tumors, which reflects the tumor growth rate, indicated that tumor growth rate always increased as the generation number increased. The tumor growth curves also illustrate this law. Similarly, the survival rate of PDX mice gradually improved with the increased generation number in GC and CRC. And generally, there was more proliferation (Ki67+) in the PDX models than in the patient tumors, which was in accordance with the results of tumor growth rate. The histological findings confirm similar histological architecture and degrees of differentiation between patient cancer tissues and PDX models with statistical analysis by GraphPad Prism 5.0.
We established four different types of PDX models successfully, and our results add to the current understanding of the establishment of PDX models and may contribute to the extension of application of different types of PDX models.
Additional file 1: Table S1. Clinical characteristics of GBM patients.
Additional file 2: Table S2. Clinical and pathological characteristics of LC patients.
Additional file 3: Table S3. Clinical characteristics of GC patients.
Additional file 4: Table S4. Clinical and pathological characteristics of CRC patients.
Zhuang Y, Zhu Y, Wang H, et al. Establishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsy. Br J Med Res. 2017;50(6):e6000.
Stewart E, Federico SM, Chen X, et al. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature. 2017;10:1038. https://doi.org/10.1038/nature23647.
Westra WH. Surgical pathology dissection: an illustrated guide. 2nd ed. New York: Springer; 2003. CrossRef
Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumors of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010.
Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. TNM classification of malignant tumors. 7th ed. Chichester: Wiley-Blackwell; 2010.
Van HP, Hulshof MC, Van LJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84. CrossRef
Edwards E, Geng L, Tan J, et al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002;62:4671–7. PubMed
- Establishment and evaluation of four different types of patient-derived xenograft models
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II